The Kate Pretty Lecture 2018, 'What Science Can Do: The Cambridge life science cluster at a pivot point', delivered by Pascal Soriot, the CEO of AstraZeneca
Duration: 55 mins 36 secs
Share this media item:
Embed this media item:
Embed this media item:
About this item
| Description: | The second lecture in this new series was entitled 'What Science Can Do: The Cambridge life science cluster at a pivot point', and was delivered by the CEO of AstraZeneca, Pascal Soriot, in his first public lecture in Cambridge. |
|---|
| Created: | 2018-03-16 10:14 | ||
|---|---|---|---|
| Collection: |
Special Lectures and Talks
Kate Pretty Lecture |
||
| Publisher: | Homerton College, University of Cambridge | ||
| Copyright: | Homerton College | ||
| Language: | eng (English) | ||
| Distribution: |
World
(not downloadable)
|
||
| Keywords: | Kate; Pretty; Homerton College; AstraZeneca; Pascal Soriot; Science; Biomedical; | ||
| Credits: |
|
||
| Categories: |
iTunes - Science iTunes - Health & Medicine |
||
| Explicit content: | No | ||
| Abstract: | The second lecture in this new series was entitled 'What Science Can Do: The Cambridge life science cluster at a pivot point', and was delivered by the CEO of AstraZeneca, Pascal Soriot, in his first public lecture in Cambridge. AstraZeneca's new £500 million global research and development centre is under construction on the Cambridge Biomedical Campus, and Homerton College counts senior AZ researchers Professor Tim Eisen and Professor Steve Rennard among the Fellowship. |
|---|---|
Transcript
Transcript:
Available at: https://www.homerton.cam.ac.uk/lifeathomerton/kateprettylectures/2018